Baltymas, UAB

[Available On-Demand]
BALTYMAS is seeking seed funding to commercialize CRT eyedrops - novel drug candidate for treating angiogenic eye diseases, in particular age-related macular degeneration (AMD).

BALTYMAS is a Lithuanian start-up biotechnology company. Founded by young scientists on the basis of the Institute of Biotechnology (Vilnius) it combines scientific experience and knowledge with enterprise for generation of novel biotechnology products. BALTYMAS develops yeast expression systems and employs them for the synthesis of native recombinant proteins. We offer yeast-expressed viral nucleocapsid proteins for use in diagnostics of viral infections and recombinant human cell proteins for fundamental and applied studies or biopharmaceutical purposes.

Currently BALTYMAS produces 29 products of 10 different recombinant proteins. We are also opened for contract studies of expression of various recombinant proteins in yeasts.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Lithuania
Year Founded:
2011
Main Therapeutic Focus:
Lead Product in Development:
CRT eyedrops
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Project manager
Baltymas, UAB